The University of Tokyo

Massachusetts Institute of Technology

The Broad Institute, Inc.

Harvard College

Shionogi Company Limited

Tohoku University

Japan Science and Technology Agency

Riken Corporation

Mochida Pharmaceutical Co., Ltd.

Ryuichiro Ishitani

Osamu Nureki

Hiroshi Nishimasu

Feng Zhang

Silvana Konermann

Patrick D Hsu

Fei Ran

Mark Daniel Brigham

Tetsuo Nagano

Nobuyuki Tanaka

Hirotatsu Kojima

Takayoshi Okabe

Chie-yu Lin

Yusuke Tateno

Junken Aoki

Junji Yamane

Alexandro Trevino

Mitsuyasu Kawaguchi

Shigeyuki Yokoyama

Manabu Katou

Shiro Kida

Mikako Shirouzu

Kazuki Saito

Yasuhiko Kanda

Chiaki Fujikoshi

Chie-Yu Lin

Masahide Odan

Yoshiyuki Kioi

Hideo Ogiso

The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.

Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems

The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.

CRISPR-Cas systems, crystal structure and uses thereof

The present invention provides a compound of formula (1), wherein R, R, R, R, R, Rand Rare as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound. 

Fused pyrazole derivative having autotaxin inhibitory activity

A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: 

Pyrimidinone derivative having autotaxin-inhibitory activity

The present invention relates to a crystal of a complex of an epidermal growth factor (EGF) and an epidermal growth factor receptor (EGFR), a crystal of a complex of EGFR and a substance regulating EGFR activity, structure coordinates of these crystals, a method for screening for the substance regulating EGFR activity, a method for designing the substance regulating EGFR activity, a method for designing an EGFR variant or an EGF variant, a method for producing an EGFR variant or an EGF variant and an EGF variant or an EGFR variant obtainable by such method, a method for designing an epitope using the structure coordinates of the EGF-EGFR complex, a method for producing an anti-EGFR antibody or an anti-EGF antibody and an antibody obtainable by such method, a polypeptide or a salt thereof comprising a region that forms an EGFR dimerization site, and the like.

EGR-EGFR complex

Growing community of inventors

Tokyo, Japan

Ryuichiro Ishitani